Breakthrough in early human embryo research
A new stem cell model, discovered by researchers exploring the human genome, will help scientists to map out the key genomic changes during early development. […]
R&D
To help solve patient distrust in pharma, industry collaboration is key
The past two years have shone a spotlight on the UK life sciences industry. Pharma companies are now household names, having been thrust into the […]
Deep Dive: Research and Development
Fuelled by advancements in technology and computing, R&D in life sciences is undergoing a fundamental transformation that puts patients at the heart of research. Read […]
How new data capabilities can supercharge clinical research
The UK’s health research data capabilities are rapidly evolving. For example, during the height of the pandemic, NIHR’s integrated health research system was able to […]
Cantex secures license to develop small molecule-drug for inflammatory lung diseases
Clinical stage pharmaceutical company Cantex Pharmaceuticals has obtained a global licence from Harvard University’s Office of Technology Development to develop the small-molecule drug azeliragon into […]
Coalition issues rallying cry to takes the fight against AMR to the front line
Team up, wake up, and act before AMR turns back the clock on medical advances, say the cross-sector team behind the Infection Management Coalition. It’s […]
Takeda grows in gene therapies again with $2bn Code Bio deal
Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for […]
TargED Bio raises €39m for new clot-busting drug
There’s been hardly any change in the use of clot-dissolving (thrombolytic) therapies for conditions like heart attack and stroke for decades, but a small Dutch […]
Synairgen slumps as inhaled COVID drug fails pivotal test
UK biotech Synairgen saw the value of its shares crater after its inhaled interferon beta therapy SNG001 was found to provide no benefit to people […]
Lilly unveils mirikizumab data in ulcerative colitis as it preps filings
Eli Lilly has reported phase 3 results with its ulcerative colitis challenger mirikizumab, as it waits for the readout of a second trial in the […]
Examining COVID’s impact on clinical research participant diversity
The clinical research industry has long struggled with participant diversity. One study found that only 5% of Black or Asian United Kingdom residents had ever […]
Dupixent falls short in phase 3 chronic spontaneous urticaria trial
Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria (CSU) who don’t respond to the only […]
Safety probe prompts GSK to halt RSV jab study in pregnant women
GlaxoSmithKline has a lot riding on its respiratory syncytial virus (RSV) vaccine, which it thinks could be a $4 billion product at peak, so investors […]
New HIV variant highlights the importance of monitoring virus mutations
Researchers discovered a highly virulent variant of HIV in the Netherlands that genetic sequence analysis suggests has been circulating since the 1990s. Approximately 38 million […]
BMS builds case for mavacamten label ahead of FDA decision
Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its […]
Sage, Biogen’s zuranolone looks approvable, but will it sell?
Last year, the first phase 3 trial of Sage Therapeutics and Biogen’s antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability […]
Equillium triples clinical pipeline with $329m Bioniz takeover
Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million […]
Stem cell therapy ‘cures’ first woman with HIV, say researchers
A woman with HIV who received a stem cell transplant to treat acute myeloid leukaemia (AML) appears to have been cured of the infection according […]
Pharma pollution ‘threatens world environment, health’; study
One in four of the world’s rivers are polluted with potentially toxic levels of pharma compounds, according to a new study. The findings point to […]
NHS said to be central to Moderna interest in UK facility
Moderna is reportedly in late-stage negotiations with the UK government that could result in a new research and manufacturing facility being set up in the […]
Why was R&D productivity up in 2021?
A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed […]
Oxurion reports stronger data for diabetic eye disease drug
Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149, in development for people with diabetic macular […]
Vaccines upstart Curevo has designs on blockbuster GSK franchise
Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental […]
Regenxbio expands MPS I gene therapy trial after first look at data
Data from the first patients enrolled into Regenxbio’s trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known […]
AZ halts development of Beta variant COVID-19 vaccine
AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted at the Beta variant of the virus, […]
FDA fast tracks Bayer’s oral anticoagulant asundexian
The FDA has granted fast-track status to Bayer’s oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer […]
Astellas says Pompe gene therapy clears safety hurdle
With the safety of gene therapies thrown into the spotlight by a series of FDA clinical holds, Astellas has said that an interim readout in […]
Importance of diversity in pharma and clinical trials
“Diversity.” It’s a word that is very commonly thrown around right now, not just in pharma and healthcare but across all industries. No matter which […]
RedHill’s oral drug boosts Veklury efficacy in severe COVID
An oral drug developed by RedHill Biopharma has reduced mortality in severe COVID-19 patients when added to therapy with corticosteroids and Gilead Science’s intravenous antiviral […]
Clarify Health’s new offering shows one way tech can help improve clinical trial diversity
The last three years in pharma have seen a growing awareness of and dissatisfaction with a trend that has plagued the industry for its whole […]
Bayer’s pipeline takes a hit as it drops eliapixant
Bayer has abandoned development of its investigational P2X3 receptor antagonist eliapixant, despite promising efficacy data in clinical trials, on what appears to be safety grounds. […]
UCB preps filings for another challenger to AZ’s Soliris
Belgian drugmaker UCB says it will be able to file not one but two new drug therapies for autoimmune disease generalised myasthenia gravis (gMG) this […]
Can Moderna’s mRNA tech overcome the HIV vaccine roadblock?
Moderna has kicked off a clinical trial of an HIV vaccine based on the same mRNA platform that underpins its COVID-19 shot – seeking to […]
Biogen’s former R&D chief Al Sandrock resurfaces at Voyager
Al Sandrock’s shock departure from Biogen in November sparked speculation about where he would show up next, and the answer came in today – gene […]
Injectable Drug Delivery 2022
Innovations in Formulation and Device Design for Enhanced Subcutaneous Delivery As Part of Europe’s leading Injectable conference series, we will assess innovations in drug product […]
Assumptions to evidence: How NINR project is solidifying UK’s remote trial know how
Remote, virtual, or decentralised clinical trials are nothing new, but COVID-19 catapulted the model into the mainstream. Now, as the sector settles back into something […]
Pharming preps filing for rare disease drug leniolisib after trial win
Pharming has taken a step closer to getting a second product to market, after its rare disease therapy leniolisib met its objectives in a pivotal […]
Synthetic control arms in clinical trials: Making it happen
Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. But what does […]
Omicron BA.2 variant more transmissible, say UK and Danish studies
The new BA.2 subvariant of Omicron is around 50% more transmissible than the original BA.1 strain, and there is somewhat conflicting evidence on its ability […]
Madrigal sings praises of NASH drug resmetirom
After a phase 3 trial win, Madrigal Pharmaceuticals reckons it could succeed where so many other companies have failed, and finally bring a drug to […]
Pfizer sees no way forward for Ionis-partnered vupanorsen
Pfizer has called time on its alliance with Ionis for cholesterol-lowering therapy vupanorsen, after a review of phase 2b data raised some questions about the […]
Digital innovation drives vaccine development
It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they […]
Daiichi makes play for share of Japan’s COVID booster market
Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new clinical trial of its mRNA-based candidate DS-5670 […]
Offshore warning as UK biotech investment rises sharply in 2021
2021 was a record year for investments in UK biotech companies, consolidating the country’s position as one of Europe’s top life science hubs and apparently […]
Paul Stoffels swiftly resurfaces as Galapagos’ next CEO
Paul Stoffels’ retirement at the end of last year after nine years as head of R&D at Johnson & Johnson was short lived – he’s […]
Moderna starts dosing patients with its Omicron COVID jab
Moderna has started human trials of an Omicron version of its COVID-19 vaccine SpikeVax, just in case a modified version will be needed to boost […]
US vs EU: How can Europe translate home-grown innovation into biotech success?
We have seen a boom in biotech initial public offerings over the last two years, but many of Europe’s offerings have migrated to the United […]
Synthetic Control Arms – ambition to action
Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out […]
Pfizer starts dosing patients with its Omicron COVID shot
Pfizer and partner BioNTech have started their clinical trial of a new version of their COVID-19 vaccine that has been specifically designed to protect against […]
PolyPhotonix raises $10m to trial sleep mask for diabetic eye disease
The UK company behind a sleep mask that aims to treat sight-robbing complications of diabetes has secured $10 million in funding that will be used […]
Team behind RECOVERY trial of COVID drugs casts its net wider
The UK scientists that ran one of the largest trials of experimental COVID-19 drugs have formed a non-profit company that will apply the methodology to […]
Chronic kidney disease: treating a silent killer
In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease. pharmaphorum caught up with […]
Covid vaccine booster raises antibody levels in fight against Omicron
A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to researchers. Research led by UCLH, UCL and […]
Biliary tract cancer drug granted orphan drug designation in US
The US regulator has granted biliary tract cancer therapy Silmitasertib orphan drug designation. There are currently no treatments for this rare cancer, and the US […]
Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access
Access to medicines is “one of the most challenging policy areas in every country in the European region” – it’s time to develop a solution […]
BioTuring enters collaboration to enable detailed single-cell RNA research
Research into single-cell sequencing has been boosted with Single Cell Discoveries and BioTuring joining forces to refine the process. The collaboration aims to “close the […]
Billionaire-backed “rejuvenation” start-up Altos Labs launches operations
Just months after the venture was unveiled, controversial biotechnology company Altos Labs has officially launched with $3 billion in funding secured from investors. Dubbed an […]
Digital health companies enabling R&D topped 2021 US investment, Rock Health says
According to Rock Health’s annual digital health funding report, US-based digital health companies enabling life sciences research and development raised $5.8 billion (£4.3 billion) in […]
CVS Health and Microsoft alliance: an example of an extended partnership
Microsoft and CVS Health have announced a new strategic alliance focusing on personalised care and accelerating digital transformation for the benefit of CVS customers and […]
Almirall and IRB Barcelona team up to tackle skin disease
Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. Almirall and IRB Barcelona […]
Clinical trial begins of lung cancer immunotherapeutic
Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of […]
Pre-Filled Syringes East Coast 2022
SMi’s 9th Annual Conference Pre-Filled Syringes East Coast Main Conference: April 25 – 26, 2022 | Workshops: April 27, 2022 Sheraton Boston Hotel, Boston, MA, USA […]
Decentralised trials: beyond the pandemic
The adoption of decentralised activities was a major factor in allowing clinical trials to continue during the early stages of the pandemic. Ben Hargreaves examines […]
Novo Nordisk moves to strengthen obesity efforts
After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics. Under […]
Sanofi places $75m bet with ABL on popular Parkinson’s drug target
Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio […]
Daiichi Sankyo says Plexxikon R&D unit will close down
Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects […]
Aldeyra builds case for troubled dry eye drug reproxalap
Prospects for Aldeyra’s dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 […]
Sarepta says early filing for DMD gene therapy may be back on
The development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the key players – Sarepta – thinks it […]
What HCPs think about mandatory vaccination
What HCPs think about mandatory vaccination The practice of making vaccinations mandatory within a population has always been controversial. Historically, the first example of this […]
Bayer trumpets $1bn CRISPR deal with Mammoth Bio
Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences. The German […]
After trial win, Novartis nabs COVID drug from Molecular Partners
There are still licensing deals to be done in the COVID-19 category it seems, after Novartis paid around $163 million to license rights to an […]
Beyond the pandemic: the potential of mRNA technology
The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology […]
Another big AI deal as Sanofi taps Exscientia for 15 new drugs
If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies […]
Putting patient perspectives at the heart of kidney cancer research
Kidney cancer is the 14th most common cancer, with approximately 400,000 new cases worldwide every year. Renal cell carcinoma (RCC) is by far the most […]
AstraZeneca goes bigger in amyloidosis with Neurimmune deal
AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the […]
Amgen pledges $1.9bn to alliance with AI specialist Generate
Fresh from a sizeable funding round that raised $370 million, artificial intelligence-based drug discovery firm Generate Biomedicines has just signed its first major partnering deal […]
Otsuka dips its toe in psychedelic waters, backing Mindset Pharma
Despite the growing interest in developing medicines based on psychedelic compounds, big pharma has seemed a bit wary of getting involved, leaving the task to […]
PureTech challenges Roche’s Esbriet in head-to-head IPF trial
Roche’s idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, and could come under renewed pressure if […]
Nine for 2022: innovation and opportunities in healthcare
In the second part of our examination of issues that will shape the course of 2022, we’ll update the ongoing impacts of the pandemic, which […]
Look out GSK, Pfizer and BioNTech are coming for Shingrix
GlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces […]
Gritstone bio trumpets first data for ‘multivariant’ COVID jab
A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response […]
Nine for 2022: International issues that are compelling, new or changed in 2022
The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a […]
Biogen looks beyond Spinraza in SMA with Ionis deal
Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company […]
Boehringer’s spesolimab data raises hope for serious skin disease
Fresh from being awarded a fast-track review from the FDA, Boehringer Ingelheim’s spesolimab has shown encouraging efficacy in a phase 2 trial in generalised pustular […]
2021 in review: Building the framework of a patient-centric industry
Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action. […]
Novartis adds gene therapy for blindness with Gyroscope buy
Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not […]
Drug development and working with specialised Rare Disease networks
There are currently an estimated 300 million people living with one or more Rare Diseases across the world. There are over 7,000 Rare Diseases that […]
Leveraging augmented analytics to drive better business decisions
In early 2020, health officials were cautious about forecasting a COVID-19 vaccine timeline to the public, as vaccine discovery was a historically laborious process that […]
Blow for Novartis as ligelizumab can’t top Xolair in phase 3
Novartis’ big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company […]
Ipsen places €480m bet on Genfit’s liver drug elafibranor
Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with […]
Mesoblast pummelled as Novartis exits COVID deal
Novartis as opted out of a collaboration with Mesoblast to develop its stem cell-based therapy remestemcel-L as a treatment for COVID-19, prompting a slump in […]
Flush with COVID cash, Pfizer tables $6.7bn bid for Arena
Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing to buy Arena Pharma and its late-stage […]
How IQVIA used real-time analytics to generate custom ads that drew thousands of diverse and highly engaged patients to a global vaccine trial
If you want to accelerate recruiting, go directly to the source: patients. It is a lesson the industry has always known, but recruiting patients during […]
2021: the year mRNA therapeutics came of age
It started with two Covid-19 vaccines – 2021 is the year interest in mRNA therapeutics boomed, reports Katrina Megget The Covid-19 pandemic showed what could […]
UCB chases after Argenx with FcRN drug for myasthenia gravis
UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor (FcRn) antibody rozanolixizumab for autoimmune disease generalised […]
Trial sets up filings for uniQure’s haemophilia gene therapy
Dutch biotech uniQure and partner CSL Behring are planning to file for approval of their gene therapy for haemophilia B, armed with new trial data […]
Acadia closer to bringing first Rett syndrome drug to market
Acadia Pharma’s trofinetide has hit its efficacy targets in a phase 3 trial involving girls with the devastating neurological disorder Rett syndrome, although safety has […]
AI specialist Recursion nabs multibillion-dollar Roche partnership
Roche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and “industrialised” drug discovery to find new neuroscience and […]
AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal
AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR). The deal is […]
Merck halts more trials of HIV candidate islatravir
Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the […]
Viagra ‘should be tested as Alzheimer’s therapy’
Scientists in the US have found that people who use Viagra for erectile dysfunction seem to have a lower risk of developing Alzheimer’s disease – […]
Novartis takes aim at risky Parkinson’s target with $1.5bn UCB deal
Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first oral, disease-modifying drug for the disease – […]
GSK pumps £30m into a new Oxford University partnership
GlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply machine learning and functional genomics to the […]
Dyno attracts $1.6bn gene therapy deal with Astellas
Astellas has signed another bolt-on deal to build its gene therapy pipeline, agreeing a deal with Dyno Therapeutics to tap into its adeno-associated virus (AAV) […]
Sanofi snaps up acne vaccine developer Origimm Bio
Sanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. The French […]
GSK poaches Pfizer exec Dormitzer as new vaccines R&D chief
GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil […]
Report suggests UK’s national vaccine facility is on the block
The UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – is rumoured to be up for sale. […]
Pharma pledges rapid response to Omicron COVID variant
With governments around the world announcing measures to curb the new B.1.1.529 variant of COVID-19 – now christened Omicron – leading vaccine manufacturers have said […]
Fall in efficacy of Merck’s molnupiravir puts Pfizer in driver’s seat
Merck & Co has reported new data with its oral antiviral molnupiravir that suggests it is not as effective against COVID-19 as originally hoped. An […]
Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?
Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed it met its main efficacy targets, but […]
Trial of intranasal Alzheimer’s vaccine gets underway in US
The first patients are now being treated as part of a first-in-human trial of a vaccine, administered as a nasal spray, that aims to slow […]
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
A year ago, Swiss biotech Santhera was slashing staff to cut costs after it abandoned lead Duchenne muscular dystrophy (DMD) therapy idebenone. Now, it’s ready […]
AstraZeneca cuts the ribbon on its $1bn R&D lab in Cambridge
After years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in Cambridge, said to be the biggest science lab […]
Chinese tech giant Baidu licenses mRNA algorithm to Sanofi
Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. […]
Next Generation Kinase Inhibitors Summit
Turbocharge the Development of the Best-In-Class Kinase Inhibitor Products, to Enhance Specificity, Overcome Resistance to Deliver Safe & Durable Clinical Responses Celebrating 20 years of […]
2nd Mitochondria-Targeted Drug Development Summit
Overcome the Challenge of Treating Unmet Medical Needs Caused by Mitochondrial Dysfunction The 2nd annual Mitochondria-Targeted Drug Development Summit returns as the only industry-led meeting focused on overcoming […]
Gilead foregoes buyout, but pledges $725m to Arcus’ cancer drugs
Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn’t go as far as the takeover […]
Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover deal
Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to […]
Novo Nordisk on seeking partnerships to expand its portfolio
Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according […]
In shock move, Biogen chief medical officer Al Sandrock will stand down
Biogen’s chief medical officer Al Sandrock has announced he will retire at the end of the year, ending a 23-year career at the biotech. The […]
Merck’s oral PCSK9 drug matches injectables in early trials
Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with […]
Poor Glycaemic Control and Tooth Loss Study
(World Diabetes Day, 14 November 2021) Largest tooth loss research study finds poor glycemic control in the over 30s results in fewer teeth In the […]
AZ, Moderna say mRNA drug is promising in heart failure
Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a […]
Legal requirement, ethical duty: How to develop compliant, useful lay summaries
New lay summary guidelines walk sponsors through their obligations under EU regulation No. 536/2014, due to come into force in February next year. Patient involvement […]
Amid crowded migraine market, Lundbeck goes its own way
The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting CGRP for many sufferers, but Lundbeck thinks […]
One world, one health: The interconnected web of antimicrobial resistance
Tackling antimicrobial resistance (AMR) requires a one health approach that joins the dots between the human, animal, and environmental drivers, consequences, and data. AMR threatens […]
Compass points to positive psilocybin trial, but shares fall
Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was effective in a phase 2b trial, although […]
One dose of Regeneron’s COVID antibody protects for eight months
A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight […]
Sanofi winds $40m into UK gene therapy firm Gyroscope
French drugmaker Sanofi has made a $40 million investment in Gyroscope Therapeutics, with another $20 million potentially on offer as the UK biotech advances its […]
Pfizer’s pill cuts COVID deaths and hospitalisations by 90%
An oral antiviral drug developed by Pfizer has been shown to dramatically cut the risk of hospitalisation or death from COVID-19 when given in the […]
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated […]
Talaris therapy ends need for immune drugs in transplant patients
Two kidney transplant patients who received a stem cell therapy developed by Talaris Therapeutics were able to come off all immunosuppressant drugs within a year, […]
Janssen on driving R&D innovation with data science
The amount of patient data has skyrocketed, providing opportunities to gain a deeper understanding of diseases that are particularly complex or areas with a high […]
The Future of Clinical Research Is Personalized: How to Increase Clinical Research Enrollment and Engagement
By Raj Sharma, Executive Director of Digital Strategy and Transformation Have you ever walked into a coffee shop and had a barista recognize you by […]
Psychedelics startup Beckley attracts Janssen neuroscience VP
Psychedelic medicines specialist Beckley Psytech has enticed a senior figure in Janssen’s neuroscience division to take on the role of its chief medical officer as […]
UK biotech Dunad inks $1.3bn Novartis deal for its protein degraders
In only its second year of operations, Cambridge, UK startup Dunad Therapeutics has already attracted a big pharma partner for its protein degradation platform. Swiss […]
AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trial
AbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving […]
Generic pill could be alternative to oral antivirals in COVID-19
A generic pill has been shown to reduce hospitalisation rates in high-risk patients with early COVID-19, potentially offering a low-cost alternative to oral antivirals from […]
Takeda buys GammaDelta to boost cancer cell therapy credentials
Japanese drugmaker Takeda has said it will exercise its option to buy UK-based GammaDelta Therapeutics, a specialist in ‘off-the-shelf’ cell therapies for solid tumours and […]
Industry welcomes boost to health research in UK budget
Groups representing the biopharma industry have welcomed an increase in health-specific R&D to £5 billion in the UK autumn budget, despite a longer timeline for […]
GSK side-lines COVID drug otilimab to focus on Xevudy
GlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – in order to focus its resources on […]
Vifor, Angion organ damage drug fails phase 3 kidney transplant study
Vifor Pharma and partner Angion Biomedica have suffered another setback with their drug to prevent organ damage, this time in high-risk kidney transplant patients. A […]
6th Microbiome Movement – Drug Development Summit Europe
Decipher Mechanisms of Action, Understand Clinical Data & Ignite Partnership Opportunities to Accelerate Your Microbiome Research Whilst emerging phase 3 data is set to ignite […]
Decentralized Clinical Research Strategies
What strategies should your organization implement to better conduct decentralized research? Join colleagues from the research community at @Advarra’s free symposium to hear how leading […]
Dupixent scores a first in rare skin disease prurigo nodularis
Sanofi and Regeneron’s Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option […]
Blow to Biogen as ALS hope tofersen flunks phase 3 trial
Already struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback after its tofersen drug for amyotrophic lateral […]
WHO plans pandemic prevention study of COVID’s origins
The World Health Organization has set up a new scientific group to study the origins of COVID-19 in the hope that it will help prevent […]
Positive safety data for long-term use of MS drug Kesimpta
Multiple sclerosis drug Kesimpta has shown promising safety data for patients who are exposed to it for extended periods. Novartis announced the findings at the […]
Spark to use CombiGene therapy to target focal epilepsy
Spark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal epilepsy, in a deal worth $8.5m in […]
J&J’s long-serving R&D chief Paul Stoffels announces retirement
Paul Stoffels is bringing a nine-year tenure as head of R&D at Johnson & Johnson to a close, announcing plans to retire at the end […]
Failed IBD trial dents confidence in BMS’ deucravacitinib
Bristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) have been hit by a mid-stage failure […]
The power of R&D collaborations to improve outcomes in rare diseases
Far more common than initially thought, rare disease treatments remain far too scarce. The answer to the problem, of course, lays in making medical research […]
Pfizer agrees $630m deal to harness Voyager’s gene therapy tech
Voyager Therapeutics has just landed a new gene therapy alliance with Pfizer that could go some way towards easing the pain of losing three other […]
Takeda halts trial of orexin drug in narcolepsy on safety grounds
Japanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had encountered a “safety signal” in the study. […]
Could Pfizer’s Inlyta have a role in Alzheimer’s disease?
Pfizer’s tyrosine kinase inhibitor Inlyta is already a cornerstone of treatment for some forms of cancer, but could have potential as a therapy for Alzheimer’s […]
Novartis’ Amit Nastik on COVID’s supply chain impact: the pharmaphorum podcast
Episode 41 of the pharmaphorum podcast heard from Amit Nastik about the impact of COVID-19 on pharma supply chains and how he and his team […]
Merck preps filings for oral COVID drug, but is it really a game changer?
Merck & Co is on the brink of plugging a gap in the coronavirus treatment armamentarium after its oral drug molnupiravir cut deaths and hospitalisations […]
Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema
Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it bought Kymab […]
Novartis drug raises hope of tackling malaria drug resistance
More than two decades ago , Novartis made a big contribution to the fight against malaria when it won approval for Coartem, the first artemisinin-based […]
UK’s clinical research recovering slower than Euro peers, says ABPI
The pandemic had a negative effect on clinical research across all countries, but the UK seems to be taking longer than others to recover, according […]
AZ claims full control of Caelum’s AL amyloidosis drug in $500m deal
AstraZeneca’s newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal that could be worth up to $500 […]
Booster data backs Pfizer, Valneva Lyme disease vaccine
Prospects for Valneva’s COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of […]
Sanofi abandons mRNA COVID jab, despite positive trial
Sanofi has said that it won’t develop its mRNA-based vaccine for COVID-19 any further, even though it seemed to work in an early-stage trial, and […]
Bad news for Biohaven as verdiperstat flunks first phase 3 test
Biohaven’s key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its […]
Treatment for all: the key steps to better representation in pharma
As people have become more conscious and vocal about diversity and inclusion, Page & Page’s Lisa Lishman says pharma should reassess how it conducts clinical […]
Capricor preps phase 3 for Duchenne cell therapy as it seeks a partner
Capricor Therapeutics’ bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data […]
Early detection of cancers will require blood sweat and tears
An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell. The […]
Roche builds evidence for Evrysdi’s benefits younger SMA patients
Roche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing its benefits when given to pre-symptomatic babies […]
5th Antifibrotic Drug Development Summit -AFDD-
The 5th Antifibrotic Drug Development Summit (AFDD) will provide you with a deeper understanding of how to progress early-stage candidates and avoid late-stage failures, know the […]
2nd Applied Biocatalysis Summit 2021
Advancing Sustainable, Streamlined Small Molecules, API and Fine Chemical Production using Enzyme Engineering & Scalable Industrial Biotransformations Attending the 2nd Applied Biocatalysis Summit is the […]
Theravance axes staff as lead pipeline drug flunks phase 3 trial
Theravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in a phase 3 trial, cutting 75% of […]
Rome Therapeutics raises $77m for junk DNA-targeting drugs
Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which were dismissed for years as ‘junk’ – […]
First subject dosed in psilocybin trial for rare headache disorder
The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), […]
AbbVie spies potential in Regenxbio eye disease gene therapy
AbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get its hands on a gene therapy for […]
France’s biotech ecosystem is primed for growth – it’s time to feed it
After some years of stagnant funding and growth France is now at an inflection point for health care innovation, says Jeito Capital’s Dr Rafaèle Tordjman. […]
Apellis reports mixed data with eye drug, but plans to file anyway
Apellis Pharma’s has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major cause of blindness – with one hit […]
Biotech Insight podcast: Overcoming planning challenges in oncology
The first episode of Kantar Health’s new Biotech Insight podcast takes aim at the planning and forecasting challenges that biotechnology companies face, with a particular […]
Server cans autism hope bumetanide after phase 3 fails
Servier and Neurochlore have been forced to admit defeat in their bid to bring the first drug to market for people with autism spectrum disorder […]
Applying the 10x Strategy to Clinical Trials: How Every New Treatment Can Move at Warp Speed
By John Potthoff, Ph.D., CEO, Elligo Imagine how many lives would be saved if we were able to develop treatments at warp speed instead of […]
Hybrigenics says it wants a merger with Bone Therapeutics
French biopharma company Hybrigenics has made another bid to merge with Belgium’s Bone Therapeutics, a specialist in regenerative medicine that is still recovering from a […]
Bayer’s eliapixant hits the right notes in PAGANINI cough study
Bayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it tries to close the gap with Merck […]
FDA slaps clinical hold on BioMarin’s PKU gene therapy
BioMarin Pharma has had another setback in its gene therapy development programme, announcing this morning that the FDA has placed a phase 1/2 trial of […]
Amgen builds case for severe asthma drug tezepelumab
Amgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in patients who also have nasal polyps, a […]
Novartis’ transplant drug hope iscalimab flunks mid-stage trial
Novartis hopes of improving on tacrolimus as the standard drug for preventing organ rejection in transplant patients have been dashed after its iscalimab candidate failed […]
Pfizer raises pressure on GSK, J&J with late-stage RSV vaccine trial
Pfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson & Johnson as the companies strive to […]
Targeting COVID-19 and cancer with immunotherapy advancements
Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes […]
J&J vaccine fails to protect women against HIV infection
Johnson & Johnson’s HIV vaccine candidate has failed its first major efficacy test, as it was unable to protect women against infection with the virus […]
AC Immune claims half a win for tau drug in Alzheimer’s trial
Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one of its objectives in a phase 2 […]
External control arms and debunking real-world data myths
For the healthcare ecosystem to drive research and care, clarity is needed about the opportunities and challenges of ECAs and their value in bringing therapies […]
‘Endless RNA’ startup Laronde raises $440m to fuel pipeline
Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed […]
GSK takes SK bio-partnered COVID jab into phase 3
As a top vaccine maker, GlaxoSmithKline has been a laggard in the COVID-19 vaccine race, but has put on a late burst of speed with […]
Data points to big win for Jardiance in hard-to-treat heart failure
The data is now in from the EMPEROR-Preserved study of Boehringer Ingelheim and Eli Lilly’s Jardiance in heart failure with preserved ejection fraction (HFpEF), and […]
After Ultomiris stumble, Alexion delivers a rare disease win for AZ
A drug for Wilson disease developed by AstraZeneca’s Alexion rare disease unit has cleared a phase 3 trial, setting up regulatory filings in the coming […]
Amplifying the patient voice for better engagement, recruitment and retention
Everyone is familiar with the phrase ‘patient-centricity’ but, where it might once have been seen as a ‘checkbox exercise’, it has gained preeminent status in […]
Merck raises pressure on Pfizer in pneumococcal vaccine tussle
Just a month after getting approval for its new pneumococcal vaccine Vaxneuvance in adults, Merck & Co has reported positive trial results in children that […]
Lilly taps Lycia for protein degrader tech in $1.6bn deal
Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal with Lycia Therapeutics spanning up to five […]
Vertex builds in gene editing yet again, with $1.2bn Arbor deal
Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of months, agreeing a partnership with CRISPR specialist […]
AZ’s Alexion takeover hits a snag, as Ultomiris flunks ALS trial
It has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the merger has already had a setback. Alexion has […]
PROVENT trial puts AZ COVID antibody combo back on track
AstraZeneca’s AZD7442 has shown that it can prevent COVID-19 infection when given to healthy patients – the first time this has been demonstrated by a […]
Does draft RCT guide set the scene for future trials?
A common set of standards for randomised clinical trials (RCTs) aims to help researchers develop the drugs and interventions of the future – no matter […]
Welcome to the COVIDome, a new tool for COVID-19 R&D
Take a cohort of people hospitalised with COVID-19 and a group of negative controls, carry out extensive biological profiling of both groups and place all […]
Health Innovators: PureTech Health’s Daphne Zohar
In latest episode of our Health Innovators video interview series, Dr Paul Tunnah speaks to Daphne Zohar, the co-founder and CEO of PureTech Health. They […]
With Alzheimer’s market opening up, Lilly forms neuroscience unit
Eli Lilly is one of the front runners in the bid to follow Biogen and Eisai onto the market with an anti-amyloid drug for Alzheimer’s […]
From start to finish – digitising clinical trials
Over the past two years, the pharma industry’s demand for automated research solutions has increased significantly and, particularly when it comes to clinical trial design, […]
Beckley Psytech raises $80m for psychedelic meds development
UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical […]
Look out Dupixent, Lilly’s lebrikizumab is on the march
Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks […]
Organicell on regenerative medicine: the pharmaphorum podcast
In the latest episode of the podcast Dominic Tyer speaks with Dr Maria Ines ‘Mari’ Mitrani, chief science officer at the clinical-stage biopharmaceutical company Organicell Regenerative […]
More malaria hope as antibody protects against infection
A single dose of a monoclonal antibody developed by scientists at the US National Institutes of Health (NIH) has provided protection for people exposed to […]
SK Bio’s COVID vaccine will start phase 3 study versus AZ jab
South Korea’s SK Bioscience has been given the all-clear to start a phase 3 trial of its COVID-19 vaccine GBP510 that will compare the shot […]
Predicting and improving clinical trial enrolment: A problem for psychiatry
Patient enrollment is a common issue across many therapeutic areas in clinical research. Psychiatric disorders in particular represent a trial area with significantly high drop-out rates […]
Kite takes the ‘Appian way’ to off-the-shelf cell therapies for cancer
Gilead Sciences’ Kite Pharma has mapped out another route to the development of allogeneic or ‘off-the-shelf’ cell therapies for cancer, using technology developed by Appia […]
Medicines Discovery Catapult relaunches Wolfson Radiochemistry facility in Manchester
Medicines Discovery Catapult (MDC) today announces the relaunch of radiochemistry at the Wolfson Molecular Imaging Centre (WMIC) in Manchester. The facility, which was closed in […]
Evaluating methods targeting Protein-Protein Interactions
Protein-protein interactions (PPIs) are becoming increasingly relevant in the pathology of many diseases, including cancer. The issue, however, is developing an effective way of targeting […]
Bayer bolsters R&D platform with $2bn Vividion takeover
Bayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will boost its ability to develop medicines against […]
Lilly has a bad hair day as Pfizer rival hits the mark in alopecia
Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair […]
Chasing Merck & Co, Bayer builds case for cough drug eliapixant
Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit […]
Novartis cleared to restart trials of new Zolgensma delivery route
The FDA has relaxed a clinical hold on clinical trials of Novartis’ intrathecal formulation of spinal muscular atrophy (SMA) gene therapy Zolgensma, allowing a new […]
Sanofi swoops on partner Translate, buying the mRNA firm for $3.2bn
Sanofi has been forging ever-closer ties with its mRNA partner Translate Bio since the two started working together in 2018, and has now gone all […]
Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases
Ipsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took the helm last year, and a flurry […]
Takeda spins norovirus vaccine out into separate company
Takeda has decided development of its norovirus vaccine candidate outside Japan will be more efficient if it is spun out into a dedicated company. The […]
Biogen adds real-world test for Aduhelm to its confirmatory trial
Biogen and partner Eisai have said they will run a large-scale observational study of Alzheimer’s drug Aduhelm in the US to build evidence for the […]
AbbVie, Calico raise their age-related disease alliance funding to $3.5bn
AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. […]
AbbVie, Calico raise their age-related disease alliance funding to $3.5bn
AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. […]
Regeneron, AZ team up on drugs for obesity “superpower” gene
AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists […]
BioNTech’s mRNA vaccine drive now includes malaria, TB shots
Flushed with the success of its COVID-19 vaccine, BioNTech has pressed the accelerator on the development of shots for other infectious diseases, and now plans […]
First published data backs CanSino’s inhaled COVID vaccine
Early-stage clinical data with CanSino Biologics’ inhaled COVID-19 vaccine show that it was able to stimulate neutralising antibodies against SARS-CoV-2 at a dose well below […]
Boehringer takes alteplase to phase 3 for COVID, but drops antibody
Boehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its thrombolytic drug alteplase, heading into a phase […]
Oncology R&D: the patient insights we’re still missing, and how to catch up
Imagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and overcrowded. You are under pressure to bring […]
Allergen builds case for first drug therapy for presbyopia
If you are in middle aged and find you have to hold your phone at arm’s length to read, you may have presbyopia – a […]
Virtual reality therapy: The future of chronic pain management?
Could virtual reality tools be effective in helping patients ‘unlearn’ their chronic pain? pharmaphorum speaks to Professor Christopher Eccleston from the University of Bath’s Centre […]
COVID-19: Celltrion’s therapeutic option
In just over a year, Celltrion Healthcare says it has identified and delivered a potential treatment for COVID-19. pharmaphorum spoke to Kwon Ki-sung, Head of […]
Look out BMS, Cytokinetics has its eye on mavacamten’s turf
Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of […]
Complex Medicines: A multi-billion-pound addition to the UK life sciences industry
A new report published by Medicines Discovery Catapult and CPI details the huge medical and market potential for complex medicines in the UK ‘Shaping […]
Ipsen tries again in Parkinson’s disease with $363m IRLAB deal
French drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden’s IRLAB for […]
GSK unveils plan for life sciences cluster at Stevenage campus
GlaxoSmithKline wants to sell more than a third of the space at its R&D campus in Stevenage, UK, to a new bioscience cluster that it […]
Virtual GP clinics – are they accessible as they need to be?
As the the pandemic accelerates a move towards remote doctors appointments, work still needs to be done to ensure that digital healthcare is easy and […]
Trials leave Galapagos’ SIK programme looking under the weather
Galapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound GLPG3970 has failed two of three clinical […]
First US patient gets total heart replacement with CARMAT device
An experimental artificial heart developed by French medical device specialist CARMAT has been implanted into the first of 10 subjects due to be enrolled in […]
Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn deal
Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the […]
AZ, J&J tweaking COVID shots to reduce clotting risks; report
AstraZeneca and Johnson & Johnson are both exploring ways to modify their COVID-19 vaccines to minimise the risk of severe blood clotting reactions that are […]
Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar
Already facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Affinivax reported positive phase 2 results with […]
Biogen builds MS pipeline via $125m deal with China’s InnoCare
Biogen has moved to shore up its besieged multiple sclerosis franchise by licensing a BTK inhibitor from Chinese biotech InnoCare currently in mid-stage clinical testing. […]
Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal
Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for […]
Taking steps towards a data-driven future for health and social care
A new policy paper promises to make it easier for innovators and developers to build and deploy tech and AI solution. So, will it help […]
Rare disease: industry, patients and tech join forces on diagnosis
Takeda’s Adam Zaeske discusses how cross-sector collaboration is shaping a brighter future for rare disease diagnosis. Diagnosis can sometimes be the most difficult part of […]
Accelerating the adoption of innovation in the NHS
Spreading innovation in the NHS is as much about fostering collaboration and building relationships as it is about designing new interventions and launching new technologies. […]
Moderna plans triple vaccine targeting flu, COVID and RSV
Buoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based shot for seasonal influenza, targeting four different […]
Dementia, cancer headline UK’s 10-year plan for life sciences sector
The UK’s long-awaited Life Sciences Vision strategy has been published, setting out the government’s stall as it tries to deliver on its promise to keep […]
A life sciences vision to deliver health, wealth and resilience for the UK
The ABPI’s chief executive Dr Richard Torbett outlines a new ‘vision’ and 10-year strategy for UK life sciences, launched by the government today. After an […]
Boehringer, Lilly hail Jardiance data in hard-to-treat heart failure
Boehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance therapy in heart failure with preserved ejection […]
